Beam Therapeutics Inc.
BEAM
$22.72
$0.984.51%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 316.19M | 17.19M | 20.12M | 24.21M | 20.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 316.19M | 17.19M | 20.12M | 24.21M | 20.04M |
| Cost of Revenue | 140.08M | 100.05M | 97.61M | 14.22M | 86.34M |
| Gross Profit | 176.12M | -82.86M | -77.49M | 9.99M | -66.30M |
| SG&A Expenses | 43.26M | 25.41M | 24.66M | 23.49M | 22.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 183.33M | 125.46M | 122.26M | 123.14M | 109.02M |
| Operating Income | 132.86M | -108.27M | -102.15M | -98.93M | -88.99M |
| Income Before Tax | 144.16M | -96.09M | -82.78M | -96.46M | -37.35M |
| Income Tax Expenses | 1.37M | -- | -- | -- | 1.00M |
| Earnings from Continuing Operations | 142.80M | -96.09M | -82.78M | -96.46M | -38.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 142.80M | -96.09M | -82.78M | -96.46M | -38.35M |
| EBIT | 132.86M | -108.27M | -102.15M | -98.93M | -88.99M |
| EBITDA | 138.22M | -103.08M | -97.33M | -94.28M | -85.04M |
| EPS Basic | 1.77 | -1.22 | -1.08 | -1.33 | -0.54 |
| Normalized Basic EPS | 1.11 | -0.72 | -0.75 | -0.72 | -0.69 |
| EPS Diluted | 1.73 | -1.22 | -1.08 | -1.33 | -0.54 |
| Normalized Diluted EPS | 1.08 | -0.72 | -0.75 | -0.72 | -0.69 |
| Average Basic Shares Outstanding | 80.86M | 79.02M | 76.34M | 72.27M | 70.78M |
| Average Diluted Shares Outstanding | 82.70M | 79.02M | 76.34M | 72.27M | 70.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
